MAIA

SEC source: 0001127602-24-013658 · form4.xml · derivative · entry 1

Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,000

Underlying: Common Stock · 141,000 shares

Expires 2034-04-26

F1 · derivative.exercise_date: The stock options, granted on April 26, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversay of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-24-013656 · form4.xml · derivative · entry 1

Himmelreich Jeffrey C · CIK 0002001189 · Head of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-04-26

F1 · derivative.exercise_date: The stock options, granted on April 26, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversay of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-24-013654 · form4.xml · derivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-04-26

F1 · derivative.exercise_date: The stock options, granted on April 26, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversay of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-24-013490 · form4.xml · derivative · entry 2

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,665

Underlying: Common Stock · 19,665 shares

Expires 2029-10-25

F2 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated April 22, 2024 and were deemed options issued under the Issuer's 2021 Equity Inventive Plan on April 25, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

SEC source: 0001127602-24-013490 · form4.xml · nonDerivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,167,189

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated April 22, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on April 25, 2024.

SEC source: 0001127602-24-013488 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 147,492

Underlying: Common Stock · 147,492 shares

Expires 2029-10-25

F3 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated April 22, 2024 and were deemed options issued under the Issuer's 2021 Equity Inventive Plan on April 25, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date.

F4 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-013488 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,005,060

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated April 22, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on April 25, 2024.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-011901 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 11,491

Underlying: Common Stock · 11,491 shares

Expires 2034-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnlogy, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficailly owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-011895 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,790

Underlying: Common Stock · 13,790 shares

Expires 2034-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-011893 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,193

Underlying: Common Stock · 9,193 shares

Expires 2034-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-011887 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,193

Underlying: Common Stock · 9,193 shares

Expires 2034-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-011882 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,193

Underlying: Common Stock · 9,193 shares

Expires 2034-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-011875 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,193

Underlying: Common Stock · 9,193 shares

Expires 2034-03-31

F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-010327 · form4.xml · derivative · entry 2

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 170,940

Underlying: Common Stock · 170,940 shares

Expires 2029-09-14

F3 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date.

F4 · ownership.nature: These securities are beneficailly owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-010327 · form4.xml · nonDerivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 857,568

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-010325 · form4.xml · derivative · entry 2

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,940

Underlying: Common Stock · 170,940 shares

Expires 2029-09-14

F2 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date.

SEC source: 0001127602-24-010325 · form4.xml · nonDerivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,147,524

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024.

SEC source: 0001127602-24-010323 · form4.xml · derivative · entry 2

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,282

Underlying: Common Stock · 69,282 shares

Expires 2029-09-14

F2 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date.

SEC source: 0001127602-24-010323 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 367,350

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024.

SEC source: 0001127602-24-010320 · form4.xml · derivative · entry 2

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,928

Underlying: Common Stock · 6,928 shares

Expires 2029-09-14

F2 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date.

SEC source: 0001127602-24-010320 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 319,600.04

F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024.

SEC source: 0001127602-24-010489 · form4.xml · derivative · entry 2

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,641

Underlying: Common Stock · 34,641 shares

Expires 2029-09-14

F1 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date.

SEC source: 0001127602-24-010489 · form4.xml · nonDerivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,891

SEC source: 0001127602-24-002276 · form4.xml · derivative · entry 1

Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-01-24

F1 · derivative.exercise_date: The stock options, granted on January 24, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-24-002270 · form4.xml · derivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-01-24

F1 · derivative.exercise_date: The stock options, granted on January 24, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-24-002267 · form4.xml · derivative · entry 1

Himmelreich Jeffrey C · CIK 0002001189 · Head of Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-01-24

F1 · derivative.exercise_date: The stock options, granted on January 24, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.

SEC source: 0001127602-24-000652 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,418

Underlying: Common Stock · 15,418 shares

Expires 2033-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-000654 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 19,273

Underlying: Common Stock · 19,273 shares

Expires 2033-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-24-000650 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,127

Underlying: Common Stock · 23,127 shares

Expires 2033-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-000645 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,418

Underlying: Common Stock · 15,418 shares

Expires 2033-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-000648 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,418

Underlying: Common Stock · 15,418 shares

Expires 2033-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-24-000643 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,418

Underlying: Common Stock · 15,418 shares

Expires 2033-12-31

F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-025164 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,378

Underlying: Common Stock · 8,378 shares

Expires 2033-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-025157 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,378

Underlying: Common Stock · 8,378 shares

Expires 2033-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-025154 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,567

Underlying: Common Stock · 12,567 shares

Expires 2033-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-025151 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,378

Underlying: Common Stock · 8,378 shares

Expires 2033-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-025144 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,378

Underlying: Common Stock · 8,378 shares

Expires 2033-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-025141 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 10,472

Underlying: Common Stock · 10,472 shares

Expires 2033-09-30

F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-019776 · form4.xml · derivative · entry 1

CHAOUKI STEVEN M · CIK 0001776865 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,910

Underlying: Common Stock · 8,910 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-019774 · form4.xml · derivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,910

Underlying: Common Stock · 8,910 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-019772 · form4.xml · derivative · entry 1

Louie Ngar Yee · CIK 0001913264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,365

Underlying: Common Stock · 13,365 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-019770 · form4.xml · derivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,910

Underlying: Common Stock · 8,910 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-019768 · form4.xml · derivative · entry 1

Theagene Jean-Manasse · CIK 0001969857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,910

Underlying: Common Stock · 8,910 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-019766 · form4.xml · derivative · entry 1

Smith Stan · CIK 0001913199 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 11,138

Underlying: Common Stock · 11,138 shares

Expires 2033-06-30

F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

F2 · ownership.nature: These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.

SEC source: 0001127602-23-017884 · form4.xml · derivative · entry 1

Vitoc Vlad · CIK 0001913257 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,760

Underlying: Common Stock · 123,760 shares

Expires 2032-05-30

F1 · derivative.exercise_date: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-017885 · form4.xml · derivative · entry 1

Obrocea Mihail · CIK 0001913265 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,495

Underlying: Common Stock · 87,495 shares

Expires 2032-05-30

F1 · derivative.exercise_date: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-017881 · form4.xml · derivative · entry 1

MCGUIRE JOSEPH F · CIK 0001243988 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,075

Underlying: Common Stock · 69,075 shares

Expires 2032-05-30

F1 · derivative.exercise_date: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-017879 · form4.xml · derivative · entry 1

Gryaznov Sergei · CIK 0001913228 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,982

Underlying: Common Stock · 75,982 shares

Expires 2032-05-30

F1 · derivative.exercise_date: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

SEC source: 0001127602-23-016379 · form4.xml · nonDerivative · entry 1

Guerrero Ramiro · CIK 0001913253 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 312,672.04

F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.40 to $2.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

SEC source: 0001127602-23-015796 · form4.xml · nonDerivative · entry 1

Luput Cristian · CIK 0001913350 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 298,068

F1 · price: The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan of Mr. Luput that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.505 to $2.74, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.